448 related articles for article (PubMed ID: 21081710)
1. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
Wiglesworth AK; Ennis KM; Kockler DR
Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
[TBL] [Abstract][Full Text] [Related]
2. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
3. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Dennis GJ
Clin Pharmacol Ther; 2012 Jan; 91(1):143-9. PubMed ID: 22130121
[TBL] [Abstract][Full Text] [Related]
4. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
5. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
Mosak J; Furie R
Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
[TBL] [Abstract][Full Text] [Related]
6. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Espinosa G; Cervera R
Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
[TBL] [Abstract][Full Text] [Related]
7. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
8. Belimumab for the management of systemic lupus erythematosus.
Lutalo PM; D'Cruz DP
Expert Opin Biol Ther; 2012 Jul; 12(7):957-63. PubMed ID: 22646798
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
10. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
11. Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B.
Drugs R D; 2010; 10(1):55-65. PubMed ID: 20509716
[TBL] [Abstract][Full Text] [Related]
12. Belimumab: a guide to its use in systemic lupus erythematosus.
Scott LJ; Burness CB; McCormack PL
BioDrugs; 2012 Jun; 26(3):195-9. PubMed ID: 22428610
[TBL] [Abstract][Full Text] [Related]
13. Belimumab: targeted therapy for lupus.
Chugh PK; Kalra BS
Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
[TBL] [Abstract][Full Text] [Related]
14. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
[TBL] [Abstract][Full Text] [Related]
15. Targeting the BLyS-APRIL signaling pathway in SLE.
La Cava A
Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
[TBL] [Abstract][Full Text] [Related]
16. Targeting BLyS in systemic lupus erythematosus.
Liu Y; La Cava A
Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):91-6. PubMed ID: 22216778
[TBL] [Abstract][Full Text] [Related]
17. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?
Stohl W
Curr Rheumatol Rep; 2012 Aug; 14(4):303-9. PubMed ID: 22547203
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
Merrill JT; Ginzler EM; Wallace DJ; McKay JD; Lisse JR; Aranow C; Wellborne FR; Burnette M; Condemi J; Zhong ZJ; Pineda L; Klein J; Freimuth WW;
Arthritis Rheum; 2012 Oct; 64(10):3364-73. PubMed ID: 22674457
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic targets in systemic lupus.
Sifuentes Giraldo WA; García Villanueva MJ; Boteanu AL; Lois Iglesias A; Zea Mendoza AC
Reumatol Clin; 2012; 8(4):201-7. PubMed ID: 22483661
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
Poh YJ; Baptista B; D'Cruz DP
Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
